-
CAIR Launches CARES Copilot 1.0: A Revolutionary AI Chatbot for Medical Diagnosis and Treatment
•
The Centre for Artificial Intelligence and Robotics (CAIR), part of the Chinese Academy of Sciences (CAS) in Hong Kong, has officially launched CARES Copilot 1.0, a cutting-edge chatbot powered by a large language model designed to assist medical professionals in diagnosis and treatment. CARES Copilot 1.0 integrates the vast knowledge…
-
VIVA Biotech Secures Licensing Deal with Lonza for Advanced Bispecific Antibody Technology
•
VIVA Biotech Holdings (HKG: 1873), a China-based Contract Research Organization (CRO), has entered into a licensing agreement with Swiss Contract Manufacturing Organization (CMO) Lonza, securing access to Lonza’s innovative bYlok bispecific pairing technology. Financial terms of the agreement were not disclosed. Lonza’s bYlok technology addresses the prevalent industry challenge of…
-
Antengene’s ATG-022 Advances to Dose Expansion Phase in Phase II CLINCH Study for Solid Tumors
•
Antengene Corporation Ltd (HKG: 6996), a leading biopharmaceutical company based in China, has announced that ATG-022, an antibody drug conjugate (ADC) targeting Claudin 18.2 (CLDN18.2), has progressed into the dosage expansion phase of the Phase II CLINCH study. This trial is evaluating ATG-022 as a monotherapy for advanced or metastatic…
-
CSPC Pharmaceutical Secures NMPA Approval for Clinical Study of SYS6023 in Advanced Solid Tumors
•
CSPC Pharmaceutical Group Ltd (HKG: 1093), a prominent China-based biopharmaceutical company, has received approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its antibody drug conjugate (ADC) SYS6023 in patients with advanced solid tumors. SYS6023 is designed to target specific receptors on tumor surfaces, allowing…
-
3SBio Reports 13.8% Revenue Growth in 2023, Driven by Strong Sales of Core Biologics
•
3SBio Inc. (HKG: 1530), a leading China-based biopharmaceutical company, has reported its 2023 financial results, achieving revenues of RMB 7.816 billion (USD 1.09 billion), reflecting a year-on-year (YOY) growth of 13.8%. Net profits rose to RMB 1.952 billion (USD 271 million), an increase of 17.7% YOY. The company’s core biologic…
-
Innovent Biologics Reports 36.2% Revenue Growth in 2023, Highlights Robust Product Sales
•
Innovent Biologics Inc. (HKG: 1801), a China-based biotechnology firm, has released its 2023 financial report, revealing a robust revenue growth of 36.2% year-on-year (YOY) to RMB 6.21 billion (USD 862 million). Product sales constituted RMB 5.73 billion (USD 796 million), marking a 38.4% YOY increase. Despite reporting a loss of…
-
Jiangsu Hengrui Receives NMPA Approval for Phase Ib/II Study of HRS2398 in Advanced Solid Tumors
•
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate an open, multi-center Phase Ib/II study. The study will assess the drug candidate HRS2398 in combination with HRS-1167 or adebrelimab…
-
Zuellig Pharma Expands Commercialization Deal for Karo Healthcare’s Lamisil in Asian Markets
•
Zuellig Pharma, a Singapore-based healthcare solutions provider, has announced the expansion of its commercialization agreement with Sweden-based Karo Healthcare. According to the new terms, Zuellig will serve as the exclusive commercialization partner for Karo’s over-the-counter (OTC) anti-fungal treatment Lamisil (terbinafine hydrochloride) across key Asian markets, including Hong Kong, Malaysia, Philippines,…
